83_FR_26598 83 FR 26488 - National Institute of Nursing Research; Notice to Close Meeting

83 FR 26488 - National Institute of Nursing Research; Notice to Close Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 110 (June 7, 2018)

Page Range26488-26488
FR Document2018-12178

Federal Register, Volume 83 Issue 110 (Thursday, June 7, 2018) 
[Federal Register Volume 83, Number 110 (Thursday, June 7, 2018)]
[Notices]
[Page 26488]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-12178]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Nursing Research; Notice to Close Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Nursing Research 
Special Emphasis Panel; Multicenter Clinical Grants.
    Date: June 6, 2018.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, 
Bethesda, MD 20817.
    Contact Person: Tamizchelvi Thyagarajan, Ph.D., Scientific 
Review Officer, National Institute of Nursing Research, National 
Institutes of Health, 6701 Democracy Boulevard, Bethesda, MD 20892, 
(301) 594-0343, [email protected].

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.361, 
Nursing Research, National Institutes of Health, HHS)

    Dated: June 1, 2018.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-12178 Filed 6-6-18; 8:45 am]
BILLING CODE 4140-01-P

26488 Federal Register / Vol. 83, No. 110 / Thursday, June 7, 2018 / Notices U.S. Patent Application 60/703,798 (2) a Pseudomonas Exotoxin A-based presumed to contain business (HHS reference E–262–2005–0–US–01), payload consisting of a PE25 variant with or confidential information and any release PCT Application PCT/US2006/028986 without alterations of one or more amino of information in these license acids in one or more B cell and/or T cell (HHS reference E–262–2005–0–PCT– applications will be made only as epitopes. 02), Australian Patent 2006275865 (HHS for the treatment of hematological required and upon a request under the reference E–262–2005–0–AU–03), malignancies.’’ Freedom of Information Act, 5 U.S.C. Canadian Patent 2616987 (HHS 552. reference E–262–2005–0–CA–04), The E–010–2016 technology discloses antibodies that recognize the BCMA (B Dated: June 1, 2018. European Patent 1910407 (HHS Cell Maturation Antigen) protein. Richard U. Rodriguez, reference E–262–2005–0–EP–05) as validated in Switzerland, Germany, BCMA is expressed on the cell surface Associate Director, Technology Transfer of several forms of cancer, most notably Center, National Cancer Institute. Spain, France, the United Kingdom, and Italy, U.S. Patent 8,907,060 (HHS multiple myeloma. Although these [FR Doc. 2018–12179 Filed 6–6–18; 8:45 am] reference E–262–2005–0–US–06), BCMA antibodies can potentially be BILLING CODE 4140–01–P European Patent 2311854 (HHS used in many therapeutic formats (e.g., reference E–262–2005–0–EP–07) as unconjugated antibodies, bispecific validated in Switzerland, Germany, antibodies (and variants thereof), DEPARTMENT OF HEALTH AND Spain, France, the United Kingdom, and antibody-drug conjugates (ADCs), HUMAN SERVICES Italy, European Patent 2332970 (HHS chimeric antigen receptors (CARs), etc., to target cancer cells for destruction, the National Institutes of Health reference E–262–2005–0–EP–08) as validated in Germany, Spain, France, contemplated field of use only concerns the development of one specific format National Institute of Nursing Research; the United Kingdom, and Italy, Notice to Close Meeting Australian Patent 2012216642 (HHS (recombinant immunotoxins) using one reference E–262–2005–0–AU–15), type of toxin variant (Pseudomonas Exotoxin A variants). Many other Pursuant to section 10(d) of the Australian Patent 2014208269 (HHS Federal Advisory Committee Act, as reference E–262–2005–0–AU–22), formats, and therefore fields of use, remain available for licensing and amended, notice is hereby given of the European Patent Application following meeting. 15191388.6 (HHS reference E–262– development. The E–263–2011–0, E–174–2011–0, The meeting will be closed to the 2005–0–EP–28), European Patent E–269–2009–0, E–292–2007, E–262– public in accordance with the 3006457 (HHS reference E–262–2005/0– 2005–0 and E–771–2013–0–5 provisions set forth in sections EP–29) as validated in Austria, Belgium, technologies (i.e., ‘‘non-E–010–2016–0 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Germany, Spain, France, the United technologies’’) all concern distinct as amended. The grant applications and Kingdom, Ireland, Italy, the variants of Pseudomonas Exotoxin A the discussions could disclose Netherlands, and Poland, European which can be used in the BCMA- confidential trade secrets or commercial Patent 3006458 (HHS reference E–262– targeted immunotoxin. The property such as patentable material, 2005–0–EP–30) as validated in Austria, Pseudomonas Exotoxin A variants and personal information concerning Belgium, Germany, Spain, France, the represent the ‘‘payload’’ portion of the individuals associated with the grant United Kingdom, Ireland, Italy, the immunotoxin, which is the portion that applications, the disclosure of which Netherlands, and Poland, Australian instigates the destruction of the cancer would constitute a clearly unwarranted Patent 2016202754 (HHS reference E– cells that are targeted by the invasion of personal privacy. 262–2005–0–AU–31), and Canadian aforementioned BCMA antibodies. Name of Committee: National Institute of Patent Application 2941466 (HHS The development of a new reference E–262–2005/0–CA–32); Nursing Research Special Emphasis Panel; therapeutic targeting BCMA will benefit Multicenter Clinical Grants. and all continuing applications and public health by offering up a treatment Date: June 6, 2018. foreign counterparts to the patents and for these cancers in instances when Time: 8:00 a.m. to 5:00 p.m. applications listed above for each conventional first line therapies are Agenda: To review and evaluate grant technology. ineffective. applications. With respect to persons who have an This notice is made in accordance Place: Bethesda Marriott Suites, 6711 with 35 U.S.C. 209 and 37 CFR part 404. Democracy Boulevard, Bethesda, MD 20817. obligation to assign their right, title and The prospective exclusive license will Contact Person: Tamizchelvi Thyagarajan, interest to the Government of the United Ph.D., Scientific Review Officer, National States of America, the patent rights in be royalty bearing, and the prospective Institute of Nursing Research, National these inventions have been assigned to exclusive license may be granted unless Institutes of Health, 6701 Democracy the Government of the United States of within fifteen (15) days from the date of Boulevard, Bethesda, MD 20892, (301) 594– America. this published notice, the National 0343, Tamizchelvi.thagarajan@nih.gov. The prospective exclusive license Cancer Institute receives written This notice is being published less than 15 territory may be worldwide and the evidence and argument that establishes days prior to the meeting due to the timing field of use may be limited to the that the grant of the license would not limitations imposed by the review and following: be consistent with the requirements of funding cycle. 35 U.S.C. 209 and 37 CFR part 404. (Catalogue of Federal Domestic Assistance ‘‘The development and commercialization In response to this Notice, the public Program Nos. 93.361, Nursing Research, of a monospecific BCMA-targeted sradovich on DSK3GMQ082PROD with NOTICES may file comments or objections. National Institutes of Health, HHS) immunotoxin, whereby the immunotoxin is Comments and objections, other than comprised of: Dated: June 1, 2018. (1) the complementary determining region those in the form of a completed license application, will not be treated Sylvia L. Neal, (CDR) sequences of either confidentially, and may be made Program Analyst, Office of Federal Advisory i. the anti-BCMA antibody known as publicly available. Committee Policy. BM24; or ii. the anti-BCMA antibody known as License applications submitted in [FR Doc. 2018–12178 Filed 6–6–18; 8:45 am] BM306; and response to this Notice will be BILLING CODE 4140–01–P VerDate Sep<11>2014 17:19 Jun 06, 2018 Jkt 244001 PO 00000 Frm 00079 Fmt 4703 Sfmt 9990 E:\FR\FM\07JNN1.SGM 07JNN1


Document Created: 2018-06-07 00:50:03
Document Modified: 2018-06-07 00:50:03
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesJune 6, 2018.
FR Citation83 FR 26488 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR